Earlier last week, I was reading a report on Dr. Robert Langer’s keynote address from the recent ARVO meeting held in Ft. Lauderdale, FL, “The Future of Regenerative Medicine in Ophthalmology”, and thought that his idea of a prototype microchip o…
Author: Irv Arons
Avastin/Lucentis Update 38: The Controversy Continues “Across the Pond”
It seems that the Brits also want to use Avastin instead of Lucentis in treating AMD, and the UK’s cost-effectiveness body of NICE (the National Institute for Health and Clinical Excellence) is taking the first steps to appraise the off-label use of …
Avastin/Lucentis Update 37: The Controversy Continues – Genentech “Paid to Play”
As I read the news release from the NEI/NIH yesterday morning, about the one-year results of the clinical trial evaluating the combination use of Lucentis with pan-retinal laser therapy to treat diabetic macular edema, prior to posting it online, and l…
Combination of Lucentis Plus Pan-Retinal Laser Achieves Vision Gain in Diabetic Macular Edema
A news release from the NEI/NIH describes how researchers have shown that the combination of retinal lasers used with Lucentis are more effective in improving vision in the treatment of diabetic retinopathy that either lasers or drugs alone. The study